Physician profile
Robert D Bieser
NPI 1386732196
$16,017.92
in general payments reported to CMS, 2019-2025
43 companies · $841 in 2025
The $841 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,781 · 2020: $1,428 · 2021: $2,522 · 2022: $3,468 · 2023: $2,851 · 2024: $2,125 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,817.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,120.69 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,661.41 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $1,261.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,157.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,143.09 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.12 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $595.42 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $516.53 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $505.04 | 2019-2023 | Spravato |
| Abbott Laboratories | $469.01 | 2021-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $429.06 | 2021-2024 | |
| Allergan, INC. | $365.12 | 2020 | |
| Merck Sharp & Dohme LLC | $363.75 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $343.05 | 2019-2023 | |
| Mylan Specialty L.P. | $291.17 | 2022-2024 | Yupelri |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bieser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.